Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Cash & Equivalents (2020 - 2025)

Maxcyte (MXCT) has disclosed Cash & Equivalents for 6 consecutive years, with $20.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 28.04% to $20.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.1 million through Dec 2025, down 28.04% year-over-year, with the annual reading at $20.1 million for FY2025, 28.04% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $20.1 million at Maxcyte, up from $13.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $239.8 million in Q1 2022, with the low at $11.1 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $49.0 million, with a median of $37.5 million recorded in 2024.
  • Peak annual rise in Cash & Equivalents hit 320.3% in 2023, while the deepest fall reached 84.22% in 2023.
  • Over 5 years, Cash & Equivalents stood at $47.8 million in 2021, then plummeted by 76.84% to $11.1 million in 2022, then skyrocketed by 320.3% to $46.5 million in 2023, then tumbled by 40.04% to $27.9 million in 2024, then decreased by 28.04% to $20.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $20.1 million, $13.0 million, and $15.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.